Kamal Adawi - 20 Oct 2025 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Role
Chief Financial Officer
Signature
/s/ Cindy Tahl, as Attorney-in-Fact
Issuer symbol
FATE
Transactions as of
20 Oct 2025
Net transactions value
$0
Form type
4
Filing time
21 Oct 2025, 16:08:42 UTC
Previous filing
06 Mar 2024
Next filing
16 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Adawi Kamal Chief Financial Officer C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO /s/ Cindy Tahl, as Attorney-in-Fact 21 Oct 2025 0001788393

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FATE Common Stock Award $0 +75,000 $0.000000 75,000 20 Oct 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FATE Stock Option (Right to Buy) Award $0 +375,000 $0.000000 375,000 20 Oct 2025 Common Stock 375,000 $1.54 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Award of restricted stock units that vest with respect to 1/4th of the underlying shares on each of November 1, 2026, November 1, 2027, November 1, 2028, and November 1, 2029, subject to the Reporting Person's continued service with the Issuer as of each such vesting date.
F2 The option shall vest as to 25% of the underlying shares on October 20, 2026 and thereafter on a monthly basis for 36 additional months, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date.